Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who acquired Applied Therapeutics securities during the specified Class Period [1]. - The lead plaintiff deadline for the lawsuit is set for February 18, 2025 [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made false and misleading statements and failed to disclose that Applied Therapeutics was not following trial protocols and good clinical practices for govorestat [3]. - This alleged misconduct created a significant risk that the trial data would be rejected by the FDA in the context of a New Drug Application [3]. Group 3: Lead Plaintiff Process - Investors in Applied Therapeutics can seek to be appointed as a lead plaintiff representative of the class by the deadline of February 18, 2025, or may choose to remain an absent class member [4]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [4].
APLT Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Applied Therapeutics, Inc. (APLT)